Meeting
2022 ASCO Annual Meeting
Patient-derived organoids to predict the drug response in locally advanced or metastatic lung cancer: A real-world study.
Authors
Chan-Yuan Zhang
Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdon, Guangzhou, China
Chan-Yuan Zhang , Han-Min Wang , Kai-Cheng Peng , Ze-Xin Chen , Jun-wei Su , Yuqing Chen , Qing-Yun Gao , Shi-Ling Zhang , Chongrui Xu , Jian Su , Hong-Hong Yan , Xuchao Zhang , Hua-Jun Chen , Jin-Ji Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9136)
DOI
10.1200/JCO.2022.40.16_suppl.9136
Abstract #
9136
Poster Bd #
122
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Optimizing supportive care for patients with metastatic lung cancer in the era of precision oncology.
First Author: Kelly Hsu
Poster
2021 ASCO Annual Meeting
Addition of selpercatinib to overcome osimertinib resistance in non-small cell lung cancer (NSCLC) with acquired RET fusion detected in ctDNA at very low allele frequency.
First Author: Leeseul Kim
Poster
2019 ASCO Annual Meeting
SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.
First Author: Geoffrey R. Oxnard
Poster
2017 ASCO Annual Meeting
Role of ERBB signaling in RET-rearranged lung cancer and contribution of EGFR amplification to cabozantinib resistance.
First Author: Roger Smith